LumiraDx Limited (LMDX)
| Market Cap | n/a |
| Revenue (ttm) | 24.94M |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
LumiraDx, a UK-based provider of point-of-care diagnostics including COVID-19 tests, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
LumiraDx Limited has filed to go public with an IPO on the NASDAQ.
A new rapid test for Covid-19 can return results in just 12 minutes, Health Minister Robin Swann has said.
LumiraDx, the next generation point-of-care diagnostic company, announced today that it has received Switzerland Federal Office of Public...
About LMDX
LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity. We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument a... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Pending |
| CEO Ron Zwanziger | Employees 1,022 |
| Stock Exchange NASDAQ | Ticker Symbol LMDX |